# Introduction to Lipidomics and the Tools Used to Analyze Lipids

UAB Metabolomics Workshop, July 2018

Paul RS Baker, PhD Director, Avanti Analytical Division























































## What are the Tools that People Use for Lipid Analysis?

## ESI LC-MS/MS

- "Soft" ionization technique allows for intact complex lipid analysis
- MS/MS enables structural elucidation and quantitation
- No derivatization
- Must have a cogent internal standard strategy for quantitation













Acqui	sition Parameters	1	Time Module	Event Pump B Conc	Parameter		01
HPLC System	ExionLC™ System	2	6.00 Pumps 10.00 Pumps	Pump B Conc. Pump B Conc			6
MS/MS System	QTRAP® 6500+ System	4	11.00 Pumps 13.00 Pumps	Pump B Conc. Pump B Conc.			98
Injection Volume	5 µL	6	13.40 Pumps 13.50 Pumps	Total Flow			0.7
Column Temp	35ºC	8	18.60 Pumps	Pump B Conc.			100
Analytical Column	Xbridge Amide 4.6 x 150 mm 3.5 um		23.00 Pumps 23.50 Pumps 23.50 Pumps 24.00 Controller	Total Flow Total Flow Stop			1.5
LC Flow Rate	700 µL/min	13					_
Mobile Phase A	5%H2O/95% ACN with 1mM ammonium acetate, pH about 8.2		100 80	Grad	ient Curve	-	
Mobile Phase B	50% H2O/50% ACN with 1mM ammonium acetate, pH is 8.2	ш %	60 - 40 -			-	
Autosampler Wash	IPA		20 -			-	
Source & MS Parameter:	ISV: 5500 V CAD: 8 GS1: 50.0 CUR: 30 GS2: 60.0 TEM: 500 DP: 60 CXP: 15 EP: 10.0		0.0 9	5.0 10.0 Tir	15.0 ne (min.)	20.0 24.0	







































#### LIPIDOMIX<sup>®</sup> Standards: Constructing Meaningful Spectra Single-vial Prepared Lipidomic Analytical Standard for Human plasma lipids Target Concentration **Mixture Component** (µg/mL) 15:0-18:1(d7) PC 75 Mouse SPLASH<sup>®</sup> 15:0-18:1(d7) PE 5 LIPIDOMIX<sup>®</sup> 15:0-18:1(d7) PS (Na Salt) 15 15:0-18:1(d7) PG (Na Salt) 4 **Quantitative Mass** 15:0-18:1(d7) PI (NH<sub>4</sub> Salt) 17 15:0-18:1(d7) PA (Na Salt) 7 **Spec Internal** 18:1(d7) Lyso PC 24 Standard 18:1(d7) Lyso PE 1 18:1(d7) Chol Ester 165 C18(Plasm)-18:1(d9) PC 16 15:0-18:1(d7) DAG 9 15:0-18:1(d7)-15:0 TAG 28 Deuterated LIPIDOMIX® standard contains all major lipid d18:1-18:1(d9) SM 15 classes in ratios relative to MOUSE plasma. C18(Plasm)-18:1(d9) PE 4

## LIPIDOMIX<sup>®</sup> Standards: Constructing Meaningful Spectra

#### Odd-Chained LIPIDOMIX<sup>®</sup> Quantitative Mass Spec Internal Standard

Mixture Component	Target Concentration (µg/mL)						
17:1 Lyso PG (Na Salt)	13						
17:1 Lyso PA (NH₄ Salt)	15						
17:1 Lyso PI (NH₄ Salt)	13						
17:1 Lyso PS (Na Salt)	13						
17:1 Lyso PC	575						
17:1 Lyso PE	12						
17:0-17:0 DAG	300						
17:0-17:0-17:0 TAG	1500						
12:0 SM (d18:1/12:0)	650						
17:0-14:1 PC	3775						
17:0-14:1 PS (NH <sub>4</sub> Salt)	180						
17:0-14:1 PG (NH <sub>4</sub> Salt)	90						
17:0-14:1 PA (NH <sub>4</sub> Salt)	15						
17:0-14:1 PE	120						
17:0-14:1 PI (NH <sub>4</sub> Salt)	200						
17:0 Chol Ester	8475						

#### Ceramide LIPIDOMIX<sup>®</sup> Quantitative Mass Spec Standard

Mixture Component	Target Concentration (ug/mL)					
C16 Ceramide (d18:1/16:0)	16.1					
C18 Ceramide (d18:1/18:0)	8.5					
C24 Ceramide (d18:1/24:0)	48.8					
C24:1 Ceramide (d18:1/24:1(15Z))	24.3					

#### Deuterated Ceramide LIPIDOMIX<sup>®</sup> Quantitative Mass Spec Internal Standard



Mixture Component	Target Concentration (µg/mL)
C16 Ceramide-d7 (d18:1-d7/16:0)	21.8
C18 Ceramide-d7 (d18:1-d7/18:0)	11.5
C24 Ceramide-d7 (d18:1-d7/24:0)	26.3
C24:1 Ceramide-d7 (d18:1-d7/24:1(15Z))	13.1







Row	Component Name	Sample Name	Num, Val.	Mean	Standard Deviation	Percent CV	Value #1	Value #2	Value #3	T
<b>P</b> 1	SM(14:0)	Bik	1 of 1	3.022e3	NA	NA	3.022e3			-
2	SM(14.0)	Sample-03	3 of 3	6.094e8	4.669e6	0.77	6.146e8	6.082e8	6.055e8	-
3	SM(14:0)	Sample-06	3 of 3	5.633e8	1.602e6	0.28	5.634e8	5.617e8	5.649e8	-
4	SM(14:0)	Sample-11	3 of 3	5.676e8	3.726e6	0.66	5.642e8	5.716e8	5.670e8	-
5	SM(14.0)	Sample-12	3 of 3	4.522e8	1.107e7	2.45	4.501e8	4.641e8	4.423e8	
6	SM(14.0)	Sample-13	3 of 3	5.502e8	6.241e6	1.13	5.517e8	5.434e8	5.556e8	
7	SM(14:0)	Sample-14	3 of 3	3.311e8	4.641e6	1.40	3.328e8	3.347e8	3.259e8	
8	SM(14:0)	Sample-15	3 of 3	4.419e8	3.259e6	0.74	4.385e8	4.451e8	4.422e8	
9	SM(14:0)	Sample-16	3 of 3	5.258e8	1.120e6	0.21	5.269e8	5.246e8	5.260e8	
10	SM(14:0)	Sample-17	3 of 3	4.759e8	9.501e5	0.20	4.762e8	4.748e8	4.765e8	
11	SM(14:0)	Sample-18	3 of 3	3.979e8	1.808e6	0.45	3.958e8	3.989e8	3.990e8	
12	SM(14:0)	Sample-19	3 of 3	5.035e8	6.440e6	1.28	5.104e8	5.023e8	4.97768	
13	SM(14:0)	Sample-20	3 of 3	4.987e8	2.869e6	0.58	4.955e8	5.009e8	4.999e8	
14	SM(14:0)	Sample-21	3 of 3	4.976e8	1.881e6	0.38	4.99268	4.955e8	4.98168	_
15	SM(14.0)	Sample-23	3 of 3	4.264e8	1.293e6	0.30	4.257e8	4.255e8	4.278e8	_
16	SM(14:0)	Sample-24	3 of 3	3.830e8	3.848e6	1.00	3.786e8	3.849e8	3.856e8	_
17	SM(14.0)	Sample-25	3 of 3	5.122e8	1.656e7	3.23	4.935e8	5.250e8	5.182e8	_
18	SM(14.0)	Sample-26	3 of 3	4.617e8	1.404e6	0.30	4.630e8	4.602e8	4.618e8	-
19	SM(14:0)	Sample-27	3 of 3	4,44568	2.23267	5.15	4,18468	4,611e8	4,54368	-
20	SM(14.0)	Sample-20	3 01 3	4.51065	2.451-6	0.22	4.02160	4.00160	4.00000	
21	SM(14.0)	Sample 20	2 4 2	4.30000	5.025+6	1.08	4,607+2	4.706+8	4.57200	_
22	SM(14-0)	Sample 31	3.43	4 30468	3 373#6	0.78	4 265+8	4.315e8	4 330+8	%CV is a function of
24	SM(14-0)	Sample-32	3.013	4 728e8	4 929+6	104	4 534+3	4 718e8	4 781e8	
25	SM(14:0)	Sample-33	3 of 3	4.491e8	6.616e6	1.47	4.418e8	4.508e8	4.547e8	lipid abundance;
26	SM(14:0)	Sample-34	3 of 3	4.579e8	4.090e6	0.89	4.618e8	4.536e8	4.583e8	low abundance
27	SM(14:0)	Sample-36	3 of 3	4.356e8	9.388e6	2.15	4,248e8	4.405e8	4.416e8	lipide will have
28	SM(14:0)	Sample-37	3 of 3	4.703e8	1.326e7	2.82	4.900e8	4.757e8	4.552e8	iipius wiii nave
29	SM(14.0)	Sample-38	3 of 3	3.107e8	5.472e5	0.18	3.107e8	3.113e8	3.102e8	higher %CVs
30	SM(14:0)	Sample-39	3 of 3	2 966e8	2.438e6	0.82	2.947e8	2 959e8	2 994e8	













### **AVANTI POLAR LIPIDS**

- Walt Shaw
- Kacee Sims
- Lisa Connell
- Steven Burgess

#### SCIEX

- Mackenzie Pearson •
- Sean Wu
- Santosh Kapil •

### SCIENTIFIC COLLABORATORS

- Kim Ekroos (Zora Bioscience) Phil Sanders (Eli Lilly) •
- •
- Jeff MacDonald (UTSW) ٠
- Ed Dennis (UCSD) •
- Dayanjan (Shanaka) Wijesinghe (VCU)
- Michael Bukowski (ÚSDA) •
- Katy Williams (UCSF) •



